A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

  title={A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.},
  author={John P. Neoptolemos and Deborah D Stocken and Helmut Friess and Claudio Bassi and Janet A Dunn and Helen Hickey and Hans G. Beger and Laureano Fern{\'a}ndez‐Cruz and Christos G. Dervenis and François Lacaine and Massimo Falconi and Paolo Pederzoli and {\'A} {\'A}kos Pap and David Spooner and David J Kerr and Markus W. B{\"u}chler},
  journal={The New England journal of medicine},
  volume={350 12},
BACKGROUND The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results. METHODS In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment with chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients to chemotherapy alone (fluorouracil… 

Figures and Tables from this paper

A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.

Postoperative adjuvant chemotherapy using cisplatin and 5-fluorouracil was safe and well tolerated; however, no clear survival benefit could be demonstrated.

Adjuvant chemoradiotherapy for high-risk pancreatic cancer.

The data supports the use of adjuvant chemoradiotherapy for high-risk pancreatic cancer, and although radiotherapy is effective in reducing local failure, effective systemic treatment is also essential.

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

The encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.

Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma

It is demonstrated that GEM-based CRT can be applied in analogy to neoadjuvant protocols in the adjuvant setting for PAC patients at high risk for disease recurrence after incomplete resection.

Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.

Major multicenter randomized studies are needed to conclusively assess the impact of neoadjuvant treatment in the management of pancreatic cancer.

Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma.

Adjuvant chemoradiotherapy was found to provide a significant additional survival benefit to surgical resection for patients with pancreatic adenocarcinoma, independent of the additional survival advantage when patients are treated at teaching facilities or high-volume centers.

Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: Final results of a randomized multi-institutional trial

Locally invasive pancreatic cancer without distant metastases or major arterial invasion is treated most effectively by surgical resection, with better survival after surgery than after radiochemotherapy.

Adjuvant Systemic Chemotherapy with Gemcitabine for Stage IV Pancreatic Cancer: A Preliminary Report of Initial Experience

Adjuvant systemic chemotherapy utilizing gemcitabine was feasible with acceptable adverse effects, and showed some survival benefit in stage IV pancreatic cancer patients, and further investigation into gem citabine-based combination therapies is warranted.

Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy.

  • T. TaniyamaC. Morizane T. Okusaka
  • Medicine
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • 2012



Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer

  • Medicine
  • 1987
Based on the original study and the confirmatory findings, the combined use of radiation therapy and fluorouracil as adjuvant therapy after curative resection is effective and is preferred to no adjUvant therapy.

Adjuvant therapy in pancreatic cancer: historical and current perspectives.

The European Study Group for Pancreatic Cancer (ESPAC)-1 trial demonstrated that the current best adjuvant treatment is chemotherapy using bolus 5-fluorouracil with folinic acid, which is as good or superior to multimodality treatments including intra-operative radiotherapy, adjUvant chemoradiotherapy and neo-adjuvant therapies.

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.

The efficacy of combined radiation and fluorouracil as adjuvant therapy for pancreatic cancer is suggested by a prospective randomized study conducted by the Gastrointestinal Tumor Study Group, which was terminated prematurely because of an unacceptably low rate of accrual.

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Adjuvant radiotherapy in combination with 5-fluorouracil is safe and well tolerated; routine use of adjuvant chemoradiotherapy is not warranted as standard treatment in cancer of the head of the pancreas or periampullary region.

Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial

Resection margin-positive pancreatic tumors represent a biologically more aggressive cancer; these patients benefit from resection and adjuvant chemotherapy but not chemoradiation; the magnitude of benefit for chemotherapy treatment is reduced for patients with R1 margins versus those with R0 margins.

Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil.

Adjuvant therapy of resected adenocarcinoma of the pancreas.